Mango🥭

Chartered Accountant - Investor. Research ➡️ Investment ➡️ Conviction

[Mango🥭 @Mango_stocks]

Avacta, with the help of the FDA, in their announcement of a single pivotal trial, dramatically increases the rNPV of AVA6000, by reducing execution uncertainly and regulatory risk!

Immense intrinsic value has been created and will. Congratulations to the team #AVCT

[Mango🥭 @Mango_stocks]

A number of exceptional headlines coming out of @avacta #AVCT today.

The fact that one is titled ‘Platform-Validating’ tells you everything about management confidence in the company.

~25% increase required to get back to 52 week highs and it’ll come but I’m super relaxed.

[Mango🥭 @Mango_stocks]

A few weeks ago, in an interview with Venture Road, @coughlin582 said that “the next data coming out in a few weeks, we believe that this dataset is really going to be validating for the platform”

The referenced data will drop sometime this week. Exciting times @avacta #AVCT

[Mango🥭 @Mango_stocks]

Expect this engineered drop to reverse quickly now #AVCT

[Mango🥭 @Mango_stocks]

Today’s news further validates and most importantly de-risks the entire pre|CISION platform. Share price should continue with its appreciation and rerate massively over the coming weeks/months!

Looking forward to the presentation at 10am #AVCT

[Mango🥭 @Mango_stocks]

#AVCT 90% disease control rate and in line with transformative P1a data. I believe this is the validation BP’s were after so over to you CC @avacta ✍️

[Avacta @avacta]

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers. https://t.co/SAS6mEx37b #AVCT

[Mango🥭 @Mango_stocks]

We’re right on the edge of a potential value inflection point:

Strong science, improving clinical results, regulatory opportunity - all converging.

SGC data is close. The market is pricing in near 0% success.

I’m excited. Watching daily.

#AVCT 🚀🔥

[Mango🥭 @Mango_stocks]

We’re now at the point where new SGC (Salivary Gland Cancer) data from @avacta could land any day and honestly this might be one of the most important updates in the company’s history.

Here’s why I’m genuinely excited👇

[Mango🥭 @Mango_stocks]

Of course, more patients and longer follow ups are needed.

Phase 1 isn’t the finish line.

But if the new SGC data confirms tumour shrinkage + safety + consistency, the risk/reward profile for Avacta shifts dramatically.

[Mango🥭 @Mango_stocks]

@avacta closing at yearly highs after healthy pull back. So much to look forward to as our next trading day takes us into December, a month of 🧨 and 🚀’s!

Triple digit share price coming sooner rather than later ⏳

#AVCT

[Mango🥭 @Mango_stocks]

@MylesMcNulty @MBdaytrading Looks like we’ll be having a proper Santa rally this year courtesy of @avacta #AVCT 🎅🏼

[Mango🥭 @Mango_stocks]

US Biotech S&P ETF breaking out to new highs. Lot’s of money flow into the sector with big names stating M&A opportunities being looked at. Bode’s well and coincides with @avacta’s announcement of P1b data due this qtr.

Partnership and/or deals announced post data IMO #AVCT

[Mango🥭 @Mango_stocks]

@TragedyCalls Haha I was thinking more like

“It’s not a lot of money now but it’ll magically multiply in a matter of months”

[Mango🥭 @Mango_stocks]

Credit to Zeus & Hughes. All placing shares look like they’ve gone into the stickiest of hands and this bodes well as we’ve now entered explosive territory 💣 Q4/Q1(26).

Criminally undervalued & looks like we’ll be seeing incremental gains over the coming weeks #AVCT

[Mango🥭 @Mango_stocks]

CC “there are partners waiting for small bits of additional data”…

��Avacta expects to release Phase 1b data for the TNBC and soft tissue sarcoma cohorts at the end of 2025’

<8 weeks to go 🤞🏼 #AVCT

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

This is interesting.

BP were waiting for AVA6207…

#AVCT